NexTel Medical Corp. Clarifies and Expands Upon Remarks Made During Recent Online Discussion

Audio By Carbonatix

ORLANDO, FL / ACCESS Newswire / August 6, 2026 / NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID:MAJI) ("NexTel" or the "Company") is issuing a clarification regarding statements made during an audio stream hosted yesterday afternoon with @SuperRobotGX.

Baylor University Research Agreement Update

During the presentation, Dr. Hausman referenced a study evaluating the anti-aging properties of Maxasome Plus in collaboration with Baylor University. NexTel clarifies that while this initiative had not been previously announced, the Company and its partner, Xycota, are currently finalizing a Material Transfer Agreement (MTA). Upon execution, product shipments to Baylor University for clinical testing are scheduled to commence next week.

Expansion of Maxasome Plus Product Line

The Company also highlighted plans to expand its product offerings with the upcoming launch of a Maxasome Plus formulation specifically tailored for household pets. NexTel anticipates introducing this veterinary formulation as its third commercial product later this year.

Increased Equity Stake in LMMY and Strategic Initiatives

Additionally, the Company discussed recent developments regarding its international partnerships. Following productive discussions and contract renegotiations with its Japanese partner, NexTel's equity ownership has increased from 70% to 75%. As a result of this renegotiation, an additional 11,277,000 shares of LMMY stock will be issued to the Company.

NexTel management further confirmed that it is actively preparing to initiate a key corporate initiative requested by shareholders since the closing of the LMMY transaction in November 2025. Additional details regarding this initiative will be disclosed as developments progress.

About NexTel Medical Corp.

NexTel Medical Corp. is a medical technology and biotechnology enterprise focused on acquiring, integrating, and commercializing high-impact medical platforms, novel therapeutic delivery technologies, and healthcare innovations.

Media & Investor Contacts:

NexTel Medical Corp.

Investor Relations & Corporate Communications

Email: [email protected]

Website: www.nextelmedical.com

SOURCE: NexTel Medical Corp